Abstract
The factors involved in the persistence of antibodies to SARS-CoV-2 are unknown. We evaluated the antibody response to SARS-CoV-2 in personnel from 10 healthcare facilities and its association with individuals’ characteristics and COVID-19 symptoms in an observational study. We enrolled 4735 subjects (corresponding to 80% of all personnel) for three time points over a period of 8-10 months. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach. In individuals positive for IgG (≥ 12 AU/mL) at the beginning of the study, we found an increase [p= 0.0002] in antibody response in symptomatic subjects, particularly with anosmia/dysgeusia (OR 2.75, 95% CI 1.753 – 4.301), in a multivariate logistic regression analysis. This may be linked to the lingering of SARS-CoV-2 in the olfactory bulb.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04387929
Funding Statement
This work was partially supported by a philantropic donation by Dolce & Gabbana, by the Italian Ministry of Health (Ricerca corrente) and by Fondazione Humanitas per la Ricerca.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This observational study has been approved by the international review board of Istituto Clinico Humanitas for all participating institutes (clinicaltrial.gov NCT04387929).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Title changed; manuscript and figure1 revised; Figure 2 added because we analyzed a new time point; Supplemental file updated.
Data Availability
Humanitas metadata are deposited in Institutional Zenodo community named IRCCS Humanitas Research Hospital & Humanitas University. The dataset and the code are available at the link https://zenodo.org/record/4528974#.YCONKXnSJaQ with restricted license however available upon request.
